Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
dc.contributor.author | Davies, A J | |
dc.contributor.author | Rohatiner, Ama | |
dc.contributor.author | Howell, Simon J | |
dc.contributor.author | Britton, K E | |
dc.contributor.author | Owens, Susan E | |
dc.contributor.author | Micallef, I N | |
dc.contributor.author | Deakin, David P | |
dc.contributor.author | Carrington, Bernadette M | |
dc.contributor.author | Lawrance, Jeremy A L | |
dc.contributor.author | Vinnicombe, S | |
dc.contributor.author | Mather, S J | |
dc.contributor.author | Clayton, Julie | |
dc.contributor.author | Foley, Ruth | |
dc.contributor.author | Jan, H | |
dc.contributor.author | Kroll, S | |
dc.contributor.author | Harris, Maggie A | |
dc.contributor.author | Amess, J | |
dc.contributor.author | Norton, Andrew J | |
dc.contributor.author | Lister, T Andrew | |
dc.contributor.author | Radford, John A | |
dc.date.accessioned | 2009-08-19T11:05:36Z | |
dc.date.available | 2009-08-19T11:05:36Z | |
dc.date.issued | 2004-04-15 | |
dc.identifier.citation | Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. 2004, 22 (8):1469-79 J. Clin. Oncol. | en |
dc.identifier.issn | 0732-183X | |
dc.identifier.pmid | 15084620 | |
dc.identifier.doi | 10.1200/JCO.2004.06.055 | |
dc.identifier.uri | http://hdl.handle.net/10541/77796 | |
dc.description.abstract | PURPOSE: An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma. PATIENTS AND METHODS: A single dosimetric dose was followed at 7 to 14 days by the patient-specific administered radioactivity required to deliver a total body dose of 0.75 Gy (reduced to 0.65 Gy for patients with platelets counts of 100 to 149 x 10(9)/L). Forty of 41 patients received both infusions. RESULTS: Thirty-one of 41 patients (76%) responded, with 20 patients (49%) achieving either a complete (CR) or unconfirmed complete remission [CR(u)] and 11 patients (27%) achieving a partial remission. Response rates were similar in both indolent (76%) and transformed disease (71%). The overall median duration of remission was 1.3 years. The median duration of remission has not yet been reached for those patients who achieved a CR or CR(u). Eleven patients continue in CR or CR(u) between 2.6+ and 5.2+ years after therapy. Therapy was well tolerated; hematologic toxicity was the principal adverse event. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia were observed in 5%, 45%, and 32% of patients, respectively. Secondary myelodysplasia has occurred in one patient. Four patients developed human antimouse antibodies after therapy. Five of 38 assessable patients have developed an elevated thyroid-stimulating hormone; treatment with thyroxine has been initiated in one patient. CONCLUSION: High overall and CR rates were observed after a single dose of tositumomab and iodine I 131 tositumomab in this patient group. Toxicity was modest and easily managed. | |
dc.language.iso | en | en |
dc.subject | Cancer Recurrence | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Antibodies, Monoclonal | |
dc.subject.mesh | Antigens, CD20 | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunoconjugates | |
dc.subject.mesh | Iodine Radioisotopes | |
dc.subject.mesh | Lymphoma, B-Cell | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Neoplasm Recurrence, Local | |
dc.subject.mesh | Radioimmunotherapy | |
dc.subject.mesh | Survival Rate | |
dc.title | Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. | en |
dc.type | Article | en |
dc.contributor.department | Cancer Research UK Medical Oncology Unit, Department of Medical Oncology, 45 Little Britain, St Bartholomew's Hospital, London EC1A 7BE, United Kingdom. Andrew.J.Davies@cancer.org.uk | en |
dc.identifier.journal | Journal of Clinical Oncology | en |
html.description.abstract | PURPOSE: An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second recurrence of indolent or transformed indolent B-cell lymphoma. PATIENTS AND METHODS: A single dosimetric dose was followed at 7 to 14 days by the patient-specific administered radioactivity required to deliver a total body dose of 0.75 Gy (reduced to 0.65 Gy for patients with platelets counts of 100 to 149 x 10(9)/L). Forty of 41 patients received both infusions. RESULTS: Thirty-one of 41 patients (76%) responded, with 20 patients (49%) achieving either a complete (CR) or unconfirmed complete remission [CR(u)] and 11 patients (27%) achieving a partial remission. Response rates were similar in both indolent (76%) and transformed disease (71%). The overall median duration of remission was 1.3 years. The median duration of remission has not yet been reached for those patients who achieved a CR or CR(u). Eleven patients continue in CR or CR(u) between 2.6+ and 5.2+ years after therapy. Therapy was well tolerated; hematologic toxicity was the principal adverse event. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia were observed in 5%, 45%, and 32% of patients, respectively. Secondary myelodysplasia has occurred in one patient. Four patients developed human antimouse antibodies after therapy. Five of 38 assessable patients have developed an elevated thyroid-stimulating hormone; treatment with thyroxine has been initiated in one patient. CONCLUSION: High overall and CR rates were observed after a single dose of tositumomab and iodine I 131 tositumomab in this patient group. Toxicity was modest and easily managed. |